Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SIM0278 in moderate-to-severe atopic dermatitis
CTR20253605Phase 2Active
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Oct 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing SIM0278 with Placebo (2 arms). Primary endpoint: Percent change from baseline in Eczema Area and Severity Index. Started Oct 2025; status: active.
02
Drugs
SIM0278
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20253605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253605.